|Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials|
Early Breast Cancer Trialists' Collaborative Group
The Lancet 366 (9503), 2087-2106, 2005
|Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013|
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
|Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015|
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
|De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017|
G Curigliano, HJ Burstein, E P Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
|Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer|
SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ...
Nature genetics 45 (4), 371-384, 2013
|Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide …|
AS Knoop, H Knudsen, E Balslev, BB Rasmussen, J Overgaard, ...
Journal of Clinical Oncology 23 (30), 7483-90, 2005
|Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical …|
MM Regan, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ...
The lancet oncology 12 (12), 1101-1108, 2011
|Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 …|
A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ...
The Lancet Oncology 17 (3), 367-377, 2016
|Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer|
TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ...
Jama 313 (13), 1347-1361, 2015
|Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial|
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The Lancet Oncology 18 (12), 1688-1700, 2017
|Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk|
FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ...
PLoS Genet 9 (3), e1003212, 2013
|The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise|
S Møller, MB Jensen, B Ejlertsen, KD Bjerre, M Larsen, HB Hansen, ...
Acta oncologica 47 (4), 506-524, 2008
|Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.|
B Kristensen, B Ejlertsen, P Dalgaard, L Larsen, SN Holmegaard, ...
Journal of Clinical Oncology 12 (5), 992-997, 1994
|Identification of six new susceptibility loci for invasive epithelial ovarian cancer|
KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ...
Nature genetics 47 (2), 164-171, 2015
|Oral clodronate in breast cancer patients with bone metastases: a randomized study|
B Kristensen, B Ejlertsen, M Groenvold, S Hein, H Loft, HT Mouridsen
Journal of internal medicine 246 (1), 67-74, 1999
|HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data|
AD Leo, C Desmedt, J Bartlett, F Piette, B Ejlertsen, KI Pritchard, ...
The lancet oncology 12 (12), 1134-1142, 2011
|Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer|
RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ...
Nature genetics 49 (12), 1767-1778, 2017
|Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer|
CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ...
Nature genetics 49 (5), 680, 2017
|Pregnancy after treatment of breast cancer–a population-based study on behalf of Danish Breast Cancer Cooperative Group|
N Kroman, MB Jensen, J Wohlfahrt, B Ejlertsen
Acta Oncologica 47 (4), 545-549, 2008
|Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial|
PE Goss, IE Smith, J O'Shaughnessy, B Ejlertsen, M Kaufmann, F Boyle, ...
The Lancet Oncology 14 (1), 88-96, 2013